Brahm H. Segal MD

Brahm Segal

Brahm H. Segal
MD

Professor of Medicine (tenured)

Department of Medicine

Jacobs School of Medicine & Biomedical Sciences


Specialty/Research Focus

Infectious Disease; Oncology

Contact Information
Roswell Park Comprehensive Cancer Center
Elm & Carlton Streets
Buffalo, NY 14263
Phone: (716) 845-5721
Fax: (716) 845-5777
bhsegal@buffalo.edu



Professional Summary:

I care for hospitalized patients and outpatients at Roswell Park Comprehensive Cancer Center, where I am head of Infectious Diseases. My area of clinical expertise relates to infections in patients with cancer and stem cell transplant recipients, and I have served on several national panels that establish guidelines for preventing, diagnosing, and managing infections in these patients. I also have a specific interest in patients with primary phagocytic disorders (e.g., chronic granulomatous disease).

Roswell Park is the site of my clinical teaching. At Roswell Park, I serve asChair of the Dept. of Internal Medicine and Chief of Infectious Diseases. I teach medical students in lecture settings and in small group sessions in their first and second years, including courses in lung pathophysiology and microbiology-immunology. I mentor residents in their clinical training and in research. I also teach fellows in all aspects of their training and mentor those who perform their research projects in my lab. I have mentored a large number of trainees in lab research, including high school and college students on summer rotations, medical students, doctoral students, and post-doctoral fellows.

Our lab research has focused on innate immune responses to infection and injury. Over the past several years, we have extended our interest in innate responses to the cancer microenvironment with the overall goals of understanding mechanisms that drive tumor progression and developing novel prognostic biomarkers and therapeutic approaches. We find that the immune pathways that mediate antimicrobial host defense can also promote metastasis and impair anti-tumor immunity. Our most recent work points to neutrophils acquiring a suppressor function within the tumor microenvironment that results in suppression of T cell proliferation and activation required for anti-tumor immunity. We identified mechanisms driving this neutrophil suppressor phenotype, including complement signaling, that are potential targets for therapeutic modulation to enhance anti-tumor immunotherapy.

Education and Training:

  • Fellowship, Infectious Diseases, National Institute of Allergy and Infectious Diseases (1999)
  • Residency, Medicine, Tufts New England Medical Center (1995)
  • MD, Albert Einstein College of Medicine (1992)

Employment:

  • Professor, Roswell Park Cancer Institute (2001-present)

Awards and Honors:

  • Top Doctors (2020)
  • UB Exceptional Scholars - Sustained Achievement (2016)
  • Fellow, Infectious Diseases Society of America (2007)
  • Fellow, American College of Physicians (2005)
  • SUNY at Buffalo Department of Medicine Award for Teaching (2001)

Research Expertise:

  • Clinical studies of infectious diseases in patients with cancer: I am head of Infectious Diseases at Roswell Park Cancer Institute. My area of clinical expertise relates to infections in patients with cancer and stem cell transplant recipients. I have served on several national panels (e.g., NCCN, IDSA, CDC) that establish guidelines for preventing, diagnosing, and managing infections in these patients. I also have a specific interest in patients with primary phagocytic disorders (e.g., chronic granulomatous disease)
  • Innate Immunity: Our current lab research relates to innate immune responses in the tumor microenvironment. Our long term goal is to develop novel therapeutic approaches to enhance anti-tumor immunity.

Grants and Sponsored Research:

  • August 2019–May 2020
    A CRISPR-based platform for testing neutrophil responses in the ovarian cancer microenvironment (3R01CA188900-05W1)
    NCI
    Role: Principal Investigator
    $207,918
  • June 2015–May 2020
    Novel Immunological Biomarkers in Ovarian Cancer Prognosis
    NIH
    Role: Principal Investigator
    $3,148,229
  • March 2016–March 2019
    The Mae Stone Goode Charitable Trust
    Role: Co-Principal Investigator
    $100,000
  • March 2016–March 2018
    Evaluation of HSCs and MSCs in ovarian cancer (PI: Dr. Thomas Cimato)
    Mae Stone Trust
    Role: Co-Investigator
    $100,000
  • March 2014–March 2016
    Evaluation of effectiveness of and immune responses to bacterial preparations
    Ventrus Biosciences Inc.
    Role: Principal Investigator
    $726,285
  • February 2009–January 2016
    Role of NADPH Oxidase in Regulating Inflammation
    NIH
    Role: Principal Investigator
    $2,176,043
  • February 2014–June 2015
    RPCI-UPCI Ovarian Cancer SPORE Developmental Research Program (PI: Kunle Odunsi): Evaluation of novel immune biomarkers for ovarian cancer
    NIH
    Role: Principal Investigator
    $50,000
  • June 2013–June 2015
    Development of Innate Immune Responses in the Tumor Microenvironment
    Roswell Park Cancer Institute
    Role: Co-Investigator
    $100,000
  • June 2012–June 2013
    Overcoming Myeloid Cell-Mediated Immunosuppression in Epithelial Ovarian Cancer
    Roswell Park Cancer Institute Tumor Immunology and Immunotherapy Program
    Role: Principal Investigator
    $30,000
  • May 2012–May 2013
    Role of NADPH Oxidase in Ataxia Telangiectasia-Related Tumorigenesis
    Wilmot Cancer Center / Roswell Park Cancer Institute pilot fund initiative
    Role: Co-Principal Investigator
    $100,000
  • April 2012–April 2013
    Overcoming Myeloid Cell-Mediated Immunosuppression to Enhance Vaccine Efficacy in Ovarian Cancer
    Pilot & Collaborative Studies for Clinical & Translational Research, Buffalo Clinical and Translational Center.
    Role: Principal Investigator
    $34,000
See all (1 more)

Journal Articles:

See all (80 more)

Evaluative Studies and Case Reports:

See all (1 more)

Presentations:

  • "NADPH oxidase limits inflammation and injury in aspiration-induced acute lung injury" American Thoracic Society (ATS) International Conference, American Thoracic Society (ATS) (2011)
  • "Nrf2 is Protective in Neutrophil-mediated Acute Lung Injury" American Thoracic Society (ATS) International Conference, American Thoracic Society (ATS) (2011)
  • "Clinical Presentation and Non-BMT Management of Patients with CGD: New Approaches" American Society of Blood and Marrow Transplantation (ASBMT),, American Society of Blood and Marrow Transplantation (ASBMT),, Chronic Granulomatous Disease (CGD): Lessons From a Rare Disorder (2011)
  • "Immune System and Management of Aspergillosis" 12th Japan Mycoses Forum (2011)
  • "NADPH Oxidase: a Master Regulator of Antifungal Host Defense and Inflammation" Gordon Research Conference, Gordon Research Conference (2011)
  • "Immunity against Aspergillosis and Aspergillus-associated Diseases" 2nd Shanghai Oriental Respiratory Disease International Forum (2010)
  • "Treatment of Aspergillosis: 2008 Guidelines of IDSA and Clinical Practice" 2nd Shanghai Oriental Respiratory Disease International Forum (2010)
  • "Aspergillosis" New York State Thoracic Society Annual Scientific Assembly, New York State Thoracic Society (2010)
  • "Conventional and novel risk factors for invasive aspergillosis" 20th Focus on Fungal Infections (2010)
  • "Sunday Brunch with the Experts: Management of Treatment-related Infections, Thromboses, and Neuropathy" National Comprehensive Cancer Network 15th Annual Conference: Clinical Practice Guidelines & Quality Care,, NCCN (2010)
  • "Aspergillosis in chronic granulomatous diseases" 4th Advances Against Aspergillosis (2010)
  • "NADPH oxidase and inflammation" 4th Advances Against Aspergillosis (2010)
See all (2 more)

Service Activities:

  • Jacobs School of Medicine & Biomedical Sciences Unqualified Promotions; Member (2011–2014)

School News:

In the Media:


Clinical Specialties:

Clinical Offices:

Insurance Accepted:



Contact Information

Roswell Park Comprehensive Cancer Center
Elm & Carlton Streets
Buffalo, NY 14263
Phone: (716) 845-5721
Fax: (716) 845-5777
bhsegal@buffalo.edu